4.2 Review

More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases

Journal

IMMUNOTHERAPY
Volume 3, Issue 3, Pages 435-441

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/IMT.10.111

Keywords

autoimmune disease; autoreactive CD4(+) T cell; IFN-gamma; T-bet; Th1 cell

Categories

Funding

  1. NIH [NS-52177, 2G12RR013646-11]
  2. National Multiple Sclerosis Society [RG3499, RG3701]

Ask authors/readers for more resources

T-bet was initially described as a T-box transcription factor with an essential role in orchestrating Th1 cell differentiation. Subsequently, it was determined that T-bet controls the expression of numerous cytokines and their receptors, adhesion molecules and chemokine receptors, and therefore determines the differentiation and development status of many types of immune cells. The critical role of T-bet in autoimmune diseases, particularly multiple sclerosis and its animal model experimental autoimmune encephalomyelitis, implicates it as a potential biomarker for pathogenic T cells as well as a therapeutic drug target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available